Kiora Pharmaceuticals, Inc.(KPRX)Earnings, Financials & Key RatiosKiora Pharmaceuticals, Inc. (KPRX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
combined with consistent quarterly operating losses, suggests a high probability of near-term dilutive financing that outweighs current clinical-stage potential.
Kiora Pharmaceuticals, Inc. (KPRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Kiora Pharmaceuticals, Inc. (KPRX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.58vs $0.71+18.3% | —vs $2M |
| Q2 2026 | Mar 25, 2026 | $1.60vs $0.67-138.8% | —vs $2M |
| Q4 2025 | Nov 7, 2025 | $0.01vs $0.72+101.4% | —vs $750,000 |
| Q3 2025 | Aug 8, 2025 | $0.54vs $0.58+6.9% | —vs $750,000 |
Recent stock market news and headlines for Kiora Pharmaceuticals, Inc. (KPRX)
Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium. Presentation Details Date: Thursday, July 9, 2026 Time: 2:30 p.m.
Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity: KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora's ongoing Phase 2 clinical program in vision restoration in patients with gene mutation-agnostic Retinitis Pigmentosa Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA.
Key metrics vs top competitors for Kiora Pharmaceuticals, Inc. (KPRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.55 | $11.3M | -0.97 | -100% | — | -51.74% | — | |
| $10.33 | $2.26B | -7.27 | -18.67% | -558.24% | -64.55% | — | |
| $5.90 | $184.99M | -2.07 | — | -519.3% | -46.82% | — | |
| $123.77 | $9.1B | -21.16 | — | — | -42.78% | — | |
| $2.23 | $134.52M | -3.98 | — | — | -0% | — | |
| $4.07 | $444.42M | -2.02 | — | — | -70.79% | — |
Kiora Pharmaceuticals, Inc. (KPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Kiora Pharmaceuticals, Inc. (KPRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 8, 2026·SEC
Apr 7, 2026·SEC
Apr 2, 2026·SEC
Get notified when KPRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Kiora Pharmaceuticals, Inc. (KPRX) stock FAQ — growth, dividends, profitability & financials explained
Kiora Pharmaceuticals, Inc. (KPRX) saw revenue decline by 100.0% over the past year.
Kiora Pharmaceuticals, Inc. (KPRX) reported a net loss of $11.1M for fiscal year 2025.
Kiora Pharmaceuticals, Inc. (KPRX) has a return on equity (ROE) of -51.7%. Negative ROE indicates the company is unprofitable.
Kiora Pharmaceuticals, Inc. (KPRX) had negative free cash flow of $10.5M in fiscal year 2025, likely due to heavy capital investments.
